(Q39844962)

English

Induction of protection against divergent H5N1 influenza viruses using a recombinant fusion protein linking influenza M2e to Onchocerca volvulus activation associated protein-1 (ASP-1) adjuvant

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

15 September 2017

Induction of protection against divergent H5N1 influenza viruses using a recombinant fusion protein linking influenza M2e to Onchocerca volvulus activation associated protein-1 (ASP-1) adjuvant (English)

1 reference

Europe PubMed Central

15 September 2017

Onchocerca volvulus

object named as

Onchocerca volvulus

1 reference

based on heuristic

inferred from title

9

object named as

Sara Lustigman

1 reference

Europe PubMed Central

15 September 2017

10

object named as

Shibo Jiang

1 reference

Europe PubMed Central

15 September 2017

2

object named as

Lanying Du

1 reference

Europe PubMed Central

15 September 2017

12

object named as

Yusen Zhou

1 reference

Europe PubMed Central

15 September 2017

4

object named as

Shihui Sun

1 reference

Europe PubMed Central

15 September 2017

7

object named as

Zhihua Kou

1 reference

Europe PubMed Central

15 September 2017

author name string

Guangyu Zhao

1

1 reference

Europe PubMed Central

15 September 2017

Wenjun Xiao

3

1 reference

Europe PubMed Central

15 September 2017

Yongping Lin

5

1 reference

Europe PubMed Central

15 September 2017

Min Chen

6

1 reference

Europe PubMed Central

15 September 2017

Yuxian He

8

1 reference

Europe PubMed Central

15 September 2017

Bo-Jian Zheng

11

1 reference

Europe PubMed Central

15 September 2017

language of work or name

0 references

publication date

21 August 2010

1 reference

Europe PubMed Central

15 September 2017

1 reference

Europe PubMed Central

15 September 2017

28

1 reference

Europe PubMed Central

15 September 2017

44

1 reference

Europe PubMed Central

15 September 2017

7233-7240

1 reference

Europe PubMed Central

15 September 2017

Characterization of an avian influenza A (H5N1) virus isolated from a child with a fatal respiratory illness

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.049

7 January 2021

Molecular epidemiology of H5N1 avian influenza.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.049

7 January 2021

Matrix protein 2 vaccination and protection against influenza viruses, including subtype H5N1

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.049

7 January 2021

Preclinical study of influenza virus A M2 peptide conjugate vaccines in mice, ferrets, and rhesus monkeys

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.049

7 January 2021

Induction of influenza type A virus-specific resistance by immunization of mice with a synthetic multiple antigenic peptide vaccine that contains ectodomains of matrix protein 2.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.049

7 January 2021

Improved design and intranasal delivery of an M2e-based human influenza A vaccine.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.049

7 January 2021

Increasing M2 epitope density enhances systemic and mucosal immune responses to influenza A virus

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.049

7 January 2021

A universal influenza A vaccine based on the extracellular domain of the M2 protein

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.049

7 January 2021

Development of a universal influenza A vaccine based on the M2e peptide fused to the papaya mosaic virus (PapMV) vaccine platform.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.049

7 January 2021

Heterologous expression, purification and characterization of the influenza A virus M2e gene fused to Mycobacterium tuberculosis HSP70(359-610) in prokaryotic system as a fusion protein

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.049

7 January 2021

Enhancement of mucosal immune response against the M2eHBc+ antigen in mice with the fusion expression products of LTB and M2eHBc+ through mucosal immunization route.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.049

7 January 2021

Potent immunogenicity and efficacy of a universal influenza vaccine candidate comprising a recombinant fusion protein linking influenza M2e to the TLR5 ligand flagellin

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.049

7 January 2021

CTA1-M2e-DD: a novel mucosal adjuvant targeted influenza vaccine.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.049

7 January 2021

rOv-ASP-1, a recombinant secreted protein of the helminth Onchocercavolvulus, is a potent adjuvant for inducing antibodies to ovalbumin, HIV-1 polypeptide and SARS-CoV peptide antigens

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.049

7 January 2021

Evaluation of recombinant Onchocerca volvulus activation associated protein-1 (ASP-1) as a potent Th1-biased adjuvant with a panel of protein or peptide-based antigens and commercial inactivated vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.049

7 January 2021

Recombinant Ov-ASP-1, a Th1-biased protein adjuvant derived from the helminth Onchocerca volvulus, can directly bind and activate antigen-presenting cells.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.049

7 January 2021

Jalview Version 2--a multiple sequence alignment editor and analysis workbench

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.049

7 January 2021

An M2e-based multiple antigenic peptide vaccine protects mice from lethal challenge with divergent H5N1 influenza viruses.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.049

7 January 2021

Intranasal vaccination of recombinant adeno-associated virus encoding receptor-binding domain of severe acute respiratory syndrome coronavirus (SARS-CoV) spike protein induces strong mucosal immune responses and provides long-term protection against

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.049

7 January 2021

Comparing the ability of a series of viral protein-expressing plasmid DNAs to protect against H5N1 influenza virus

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.049

7 January 2021

Evaluation of conserved and variable influenza antigens for immunization against different isolates of H5N1 viruses.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.049

7 January 2021

High epitope density in a single recombinant protein molecule of the extracellular domain of influenza A virus M2 protein significantly enhances protective immunity

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.049

7 January 2021

An influenza A vaccine based on tetrameric ectodomain of matrix protein 2.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.049

7 January 2021

Influenza A vaccine based on the extracellular domain of M2: weak protection mediated via antibody-dependent NK cell activity.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.049

7 January 2021

Treatment of influenza virus-infected SCID mice with nonneutralizing antibodies specific for the transmembrane proteins matrix 2 and neuraminidase reduces the pulmonary virus titer but fails to clear the infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.049

7 January 2021

Therapeutic potential of a fully human monoclonal antibody against influenza A virus M2 protein

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.049

7 January 2021

The co-administration of CpG-ODN influenced protective activity of influenza M2e vaccine.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.049

7 January 2021

H5N1 viruses and vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.049

7 January 2021

Heterosubtypic protection conferred by combined vaccination with M2e peptide and split influenza vaccine.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.049

7 January 2021

Universal M2 ectodomain-based influenza A vaccines: preclinical and clinical developments.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.049

7 January 2021

Induction of proinflammatory cytokines in human macrophages by influenza A (H5N1) viruses: a mechanism for the unusual severity of human disease?

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.049

7 January 2021

Proinflammatory cytokine responses induced by influenza A (H5N1) viruses in primary human alveolar and bronchial epithelial cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.049

7 January 2021

Delayed antiviral plus immunomodulator treatment still reduces mortality in mice infected by high inoculum of influenza A/H5N1 virus

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.049

7 January 2021

Influenza A virus M2 protein: monoclonal antibody restriction of virus growth and detection of M2 in virions

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2010.08.049

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/J.VACCINE.2010.08.049

1 reference

Europe PubMed Central

15 September 2017

1 reference

Europe PubMed Central

15 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q39844962&oldid=2091392362"